Literature DB >> 1479579

2-(aminoalkyl)-5-nitropyrazolo[3,4,5-kl]acridines, a new class of anticancer agents.

D B Capps1, J Dunbar, S R Kesten, J Shillis, L M Werbel, J Plowman, D L Ward.   

Abstract

2-(Aminoalkyl)-5-nitropyrazolo[3,4,5-kl]acridines were prepared from substituted anilines via the 1-chloro-4-nitroacridones followed by condensation with [(alkylamino)alkyl]hydrazines. Impressive activity was demonstrated for the 9-hydroxy, 9-alkoxy, and 9-acyloxy analogs in vitro on a L1210 leukemia line and in vivo against the P388 leukemia. Advanced studies led to the selection of 3bbb for clinical trial.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479579     DOI: 10.1021/jm00104a001

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Activity of the pyrazoloacridines against multidrug-resistant tumor cells.

Authors:  J Sebolt; M Havlick; K Hamelehle; J Nelson; W Leopold; R Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.

Authors:  E Claire Dees; Eric K Rowinsky; Dennis A Noe; Seamus O'Reilly; Alex A Adjei; Kathy Elza-Brown; Ross C Donehower
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

3.  Utilizing Genome-Wide mRNA Profiling to Identify the Cytotoxic Chemotherapeutic Mechanism of Triazoloacridone C-1305 as Direct Microtubule Stabilization.

Authors:  Jarosław Króliczewski; Sylwia Bartoszewska; Magdalena Dudkowska; Dorota Janiszewska; Agnieszka Biernatowska; David K Crossman; Karol Krzymiński; Małgorzata Wysocka; Anna Romanowska; Maciej Baginski; Michal Markuszewski; Renata J Ochocka; James F Collawn; Aleksander F Sikorski; Ewa Sikora; Rafal Bartoszewski
Journal:  Cancers (Basel)       Date:  2020-04-02       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.